Suggestions(1)
Exact(2)
After 12 months of treatment, 38% of patients compliant to treatment A and 25% of patients compliant to treatment B had received remission (DAS28 < 2.6).
A 67-year-old male with myelodysplastic syndrome-derived overt leukemia received remission induction therapy (IDA, Ara-C) on the day of hospitalization.
Similar(58)
This trial noted a significant median survival benefit of only 10 weeks for patients receiving remission induction therapy.
Forty-one patients receiving remission induction chemotherapy with vincristine, adriamycin and prednisolone (VAP) for high grade lymphoma or acute lymphoblastic leukaemia were entered into a double blind, placebo controlled trial of oral acyclovir prophylaxis against herpes simplex virus (HSV) infection.
Most of the patients with acute leukemia were receiving remission-induction chemotherapy prior to ICU admission.
Patients were excluded if they were currently receiving remission-inducing drugs such as methotrexate or immunosuppressive medications or had received them within the past three months.
Patients were excluded if they were currently receiving remission-inducing drugs such as methotrexate or immunosuppressive medications or had received them within the past 3 months.
Additionally, the survey relied on self-reported data related to treatment received and remission status.
First, we studied the 38 individuals who received diabetes remission within one year in order to correlate their FFA levels with improved metabolic markers.
While in the Cambridge study, patients did not use concomitant immunosuppressive drugs, received RTX remission maintenance during two years and were only re-treated with RTX in case of relapse [ 7].
A multivariate function including Adr and Ara-C results was obtained which resulted in 84% of patients correctly classified as sensitive or resistant to the agents received in remission-induction therapy.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com